Q3 FY2026 · ended Sep 30, 2026 · Revenue $24.04M, +10.4% YoY · Filed Nov 5, 2026
Biodesix, Inc. (BDSX) files with the SEC under industry code 8071, Services-Medical Laboratories. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $24.0 million and a net loss of $8.0 million. Free cash flow was -$7.8 million. As of Sep 30, 2026 it held $28.4 million in cash and investments and $75.3 million in total debt.
Revenue
$24.04M
+10.4% vs year-ago quarter
Net income
$-8.03M
+7.8% vs year-ago quarter
Operating cash flow
$-7.20M
+18.9% vs year-ago quarter
Free cash flow
$-7.76M
+13.1% vs year-ago quarter
EPS
$-0.75
+35.3% vs year-ago quarter
Dividend per share
None
Shares outstanding
11.09M
+39.4% vs year-ago quarter
Net cash
$-46.88M
Q3 FY2026
Operating margin
-18.7%
TTM
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- BDSX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Louisville, CO
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1439725
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $24.0M | $26.9M | $25.6M | $28.8M | $21.8M |
| Operating income | -$6.1M | -$5.4M | -$6.2M | -$2.0M | -$7.1M |
| Net income | -$8.0M | -$7.3M | -$7.8M | -$4.0M | -$8.7M |
| Diluted EPS | -$0.75 | -$0.71 | -$0.81 | -$0.49 | -$1.16 |
| Operating cash flow | -$7.2M | -$1.6M | -$10.2M | $778,000 | -$8.9M |
| Free cash flow | -$7.8M | -$1.8M | -$10.2M | $692,000 | -$8.9M |
| Total assets | $93.9M | $95.3M | $94.6M | $87.5M | $88.7M |
| Total liabilities | $85.3M | $86.2M | $85.5M | $89.9M | $90.4M |
| Stockholders' equity | $8.7M | $9.1M | $9.1M | -$2.5M | -$1.7M |
| Cash and investments | $28.4M | $30.0M | $25.6M | $19.0M | $16.6M |
| Total debt | $75.3M | $75.0M | $75.1M | $75.4M | $75.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Nov 5, 2026 | Nov 2, 2026 |
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 20, 2026 | May 19, 2026 |
All 600 Biodesix, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.